Latest news with #acuteIschemicStroke
Associated Press
22-05-2025
- Business
- Associated Press
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
MINNEAPOLIS--(BUSINESS WIRE)--May 22, 2025-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one meetings with investors to discuss the company's strategy, recent developments and future outlook in greater detail. Presentation Details: Date & Time: June 4, 2025, 12:50 PM Eastern Time Location: New York City, NY About DM199 (rinvecalinase alfa) DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. In the treatment of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at View source version on CONTACT: Scott Kellen Chief Financial Officer Phone: (763) 496-5118 [email protected] Investor Inquiries: Mike Moyer Managing Director, LifeSci Advisors, LLC [email protected] KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA NEW YORK INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS SOURCE: DiaMedica Therapeutics Inc. Copyright Business Wire 2025. PUB: 05/22/2025 08:30 AM/DISC: 05/22/2025 08:29 AM
Yahoo
22-05-2025
- Health
- Yahoo
Acute Ischemic Stroke Market Research 2025-2035: Market Expands Amid Healthcare Investment, Technological Progress, and Emerging Market Demand
The global acute ischemic stroke market is poised for growth due to rising lifestyle disorder incidences such as hypertension, diabetes, and obesity, which elevate stroke risks. The demand for effective stroke treatments drives the market, with advanced therapies like tPA and thrombectomy improving outcomes, although challenges persist, especially in low-resource areas lacking necessary infrastructure. High treatment costs also impact accessibility. However, ongoing research and collaborations are enhancing therapeutic options. With diverse players and segmentation by therapeutics and regions, the market's expansion is fueled by increasing investments and emerging markets like Asia-Pacific. Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Acute Ischemic Stroke Market - A Global and Regional Analysis: Focus on Therapeutics, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to acute ischemic stroke occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to a sudden loss of neurological function. This blockage deprives brain tissue of essential oxygen and nutrients, causing cell death and potential long-term of the significant drivers of the global acute ischemic stroke market is the rising incidence of lifestyle disorders. The rising ages and lifestyle-related diseases such as hypertension, diabetes, and obesity which leads to increases the risk of ischemic stroke. This results in increasing demand of drug or therapies during the the positive growth trajectory, several challenges continue to impact the global acute ischemic stroke market. One of the primary challenges is limited access to advanced care in low-resource settings. However, the advanced treatments like tPA and thrombectomy have improved outcomes, many regions lack the necessary infrastructure to deliver these therapies. This results in underdiagnosis and delayed treatments, significantly increasing stroke-related disability and global acute ischemic stroke market is also facing high cost of treatment. However, the cost of cutting-edge treatments like mechanical thrombectomy, tPA, and post-stroke rehabilitation can be prohibitive for patients and healthcare systems, particularly in developing companies play pivotal roles in advancing the treatment landscape for ischemic stroke through the development of targeted therapies. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this competitive landscape of the global acute ischemic stroke market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the acute ischemic stroke market will continue to evolve, fostering new opportunities for both established and emerging global acute ischemic stroke market is on track for continued growth, driven by the growing healthcare investments and research. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for acute ischemic stroke market rises the therapies, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems. Companies Featured Acticor Biotech Bristol-Myers Squibb Genentech, Inc Athersys|Healios K.K. Biogen Inc AbbVie Revalesio Corporation NoNO Inc. Bayer TrueBinding, Inc Lumosa Therapeutics Janssen Pharmaceutical Silver Creek Pharmaceuticals Key Topics Covered:1. Global Acute Ischemic Stroke Market: Industry Outlook1.1 Overview1.2 Regulatory Landscape of Acute Ischemic Stroke1.3 Acute Ischemic Stroke Market, Epidemiology Analysis1.4 Acute Ischemic Stroke Market, Patent Landscape1.4.1 By Country1.4.2 By Year1.5 Acute Ischemic Stroke Market, Clinical Trials Landscape1.6 Key Trends1.7 Market Dynamics1.7.1 Impact Analysis1.7.2 Market Drivers1.7.3 Market Restraints1.7.3 Market Opportunities2. Global Acute Ischemic Stroke Market, By Therapeutics, $Million, 2023-20352.1 Thrombolytic Therapies2.2 Antiplatelet Therapies2.3 Antihypertensive Therapies2.4 Anticoagulants3. Global Acute Ischemic Stroke Market, by Region, $Million, 2023-20353.1 North America3.1.1 Key Findings in North America3.1.2 Business Drivers3.1.3 Business Challenges3.1.4 Market Sizing and Forecast3.1.4.1 North America Acute Ischemic Stroke Market, By Country3.1.4.1.1 U.S.3.2 Europe3.2.1 Key Findings in Europe3.2.2 Business Drivers3.2.3 Business Challenges3.2.4 Market Sizing and Forecast3.2.4.1 Europe Acute Ischemic Stroke Market, By Country3.2.4.1.1 Germany3.2.4.1.2 U.K.3.2.4.1.3 France3.2.4.1.4 Italy3.2.4.1.5 Spain3.3 Asia-Pacific3.3.1 Key Findings in Asia-Pacific3.3.2 Business Drivers3.3.3 Business Challenges3.3.4 Market Sizing and Forecast3.3.4.1 Asia-Pacific Acute Ischemic Stroke Market, By Country3.3.4.1.1 Japan4. Competitive Landscape and Company Profiles4.1 Competitive Landscape4.1.1 New Offerings4.1.2 Mergers and Acquisitions4.1.3 Partnerships, Alliances, and Business Expansion4.1.4 Funding Activities4.1.5 Regulatory Approvals4.2 Company Profiles4.2.1 Overview4.2.2 Product Portfolio4.2.3 Target Customers4.2.4 Key Professionals4.2.5 Analyst ViewFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
